Details of the Drug

General Information of Drug (ID: DM4ZS8M)

Drug Name
Nefazodone
Synonyms
Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Depression 6A70-6A7Z Withdrawn from market [2], [3]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 470
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 20% [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.5 mL/min/kg [6]
Elimination
0.1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 4 hours [6]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.23681 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [6]
Vd
The volume of distribution (Vd) of drug is 0.22-0.87 L/kg [8]
Chemical Identifiers
Formula
C25H32ClN5O2
IUPAC Name
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
Canonical SMILES
CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
InChI
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
InChIKey
VRBKIVRKKCLPHA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4449
ChEBI ID
CHEBI:7494
CAS Number
83366-66-9
DrugBank ID
DB01149
TTD ID
D0X7DE
VARIDT ID
DR00468
INTEDE ID
DR1135
ACDINA ID
D00460

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [9], [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Major depressive disorder
ICD Disease Classification 6A70.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2C receptor (HTR2C) DTT HTR2C 1.02E-02 -0.45 -0.37
5-HT 2C receptor (HTR2C) DTT HTR2C 2.27E-01 0.27 0.6
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.59E-01 6.29E-02 3.14E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 4.84E-01 -8.38E-02 -8.46E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.66E-01 4.25E-02 1.20E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.75E-01 5.15E-02 3.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nefazodone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Nefazodone and Vilazodone. Depression [6A70-6A7Z] [39]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Nefazodone and Vortioxetine. Depression [6A70-6A7Z] [40]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Nefazodone and Isocarboxazid. Depression [6A70-6A7Z] [41]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Nefazodone and Milnacipran. Depression [6A70-6A7Z] [40]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Nefazodone and Escitalopram. Depression [6A70-6A7Z] [40]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Nefazodone and Desvenlafaxine. Depression [6A70-6A7Z] [40]
OPC-34712 DMHG57U Major Decreased metabolism of Nefazodone caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [42]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Nefazodone and Clomipramine. Depression [6A70-6A7Z] [40]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Nefazodone and Esketamine. Depression [6A70-6A7Z] [43]
⏷ Show the Full List of 9 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Nefazodone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Nefazodone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [43]
Clindamycin DM15HL8 Moderate Decreased metabolism of Nefazodone caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [44]
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Nefazodone and Methylene blue. Acquired methaemoglobinaemia [3A93] [45]
Ivosidenib DM8S6T7 Major Decreased metabolism of Nefazodone caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Midostaurin DMI6E0R Major Decreased metabolism of Nefazodone caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [47]
Idarubicin DMM0XGL Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [48]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Nefazodone caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [49]
Oliceridine DM6MDCF Major Decreased metabolism of Nefazodone caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [50]
Ivabradine DM0L594 Major Decreased metabolism of Nefazodone caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [43]
Bepridil DM0RKS4 Moderate Decreased metabolism of Nefazodone caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [51]
Dronedarone DMA8FS5 Major Decreased metabolism of Nefazodone caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [43]
Bedaquiline DM3906J Moderate Decreased metabolism of Nefazodone caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [52]
Cilostazol DMZMSCT Major Decreased metabolism of Nefazodone caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [53]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nefazodone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [53]
Budesonide DMJIBAW Major Decreased metabolism of Nefazodone caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [54]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Nefazodone and Desipramine. Attention deficit hyperactivity disorder [6A05] [40]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nefazodone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [55]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Nefazodone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Nefazodone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Cariprazine DMJYDVK Major Decreased metabolism of Nefazodone caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [57]
Erdafitinib DMI782S Major Decreased metabolism of Nefazodone caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [58]
Pexidartinib DMS2J0Z Major Decreased metabolism of Nefazodone caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [59]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Nefazodone caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
HKI-272 DM6QOVN Major Decreased metabolism of Nefazodone caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
LY2835219 DM93VBZ Major Decreased metabolism of Nefazodone caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Nefazodone caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [63]
Tucatinib DMBESUA Moderate Decreased metabolism of Nefazodone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Palbociclib DMD7L94 Major Decreased metabolism of Nefazodone caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Nefazodone caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Bosutinib DMTI8YE Major Decreased metabolism of Nefazodone caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Nefazodone caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Macitentan DMP79A1 Major Decreased metabolism of Nefazodone caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [66]
PF-04449913 DMSB068 Major Decreased metabolism of Nefazodone caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [67]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Nefazodone caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [68]
Indacaterol DMQJHR7 Minor Decreased metabolism of Nefazodone caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [69]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Nefazodone and Dihydrocodeine. Chronic pain [MG30] [70]
Levomilnacipran DMV26S8 Major Decreased metabolism of Nefazodone caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [45]
Regorafenib DMHSY1I Moderate Decreased metabolism of Nefazodone caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [43]
Drospirenone DM1A9W3 Major Decreased metabolism of Nefazodone caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [43]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Nefazodone caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [51]
Ulipristal DMBNI20 Minor Decreased metabolism of Nefazodone caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [53]
Mestranol DMG3F94 Moderate Decreased metabolism of Nefazodone caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [63]
Osilodrostat DMIJC9X Major Decreased metabolism of Nefazodone caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [53]
Ivacaftor DMZC1HS Major Decreased metabolism of Nefazodone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [43]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Nefazodone caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [43]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Nefazodone caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [71]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Nefazodone and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [72]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Nefazodone caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [63]
Ospemifene DMC4GEI Moderate Decreased metabolism of Nefazodone caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [73]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Nefazodone and Ingrezza. Dystonic disorder [8A02] [74]
Cenobamate DMGOVHA Moderate Increased metabolism of Nefazodone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nefazodone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [53]
Lacosamide DMVM6QR Moderate Decreased metabolism of Nefazodone caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Cannabidiol DM0659E Minor Decreased metabolism of Nefazodone caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [53]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Nefazodone caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [76]
Tazemetostat DMWP1BH Major Decreased metabolism of Nefazodone caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [77]
Solifenacin DMG592Q Major Decreased metabolism of Nefazodone caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [43]
Mirabegron DMS1GYT Minor Decreased metabolism of Nefazodone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [78]
Itraconazole DMCR1MV Moderate Decreased metabolism of Nefazodone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [79]
Ripretinib DM958QB Major Decreased metabolism of Nefazodone caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Sunitinib DMCBJSR Moderate Decreased metabolism of Nefazodone caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Avapritinib DMK2GZX Major Decreased metabolism of Nefazodone caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [53]
Colchicine DM2POTE Major Decreased metabolism of Nefazodone caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [80]
Simeprevir DMLUA9D Major Decreased metabolism of Nefazodone caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [43]
Daclatasvir DMSFK9V Major Decreased metabolism of Nefazodone caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [53]
Rifapentine DMCHV4I Moderate Increased metabolism of Nefazodone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [81]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Nefazodone and Procarbazine. Hodgkin lymphoma [2B30] [41]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [82]
MK-1439 DM215WE Minor Decreased metabolism of Nefazodone caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fosamprenavir DM4W9B3 Minor Decreased metabolism of Nefazodone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Fostemsavir DM50ILT Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [85]
Dolutegravir DMCZGRE Minor Decreased metabolism of Nefazodone caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Saquinavir DMG814N Moderate Decreased metabolism of Nefazodone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Etravirine DMGV8QU Moderate Increased metabolism of Nefazodone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Nefazodone caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Maraviroc DMTL94F Major Decreased metabolism of Nefazodone caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Nefazodone and Mipomersen. Hyper-lipoproteinaemia [5C80] [89]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Nefazodone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [90]
BMS-201038 DMQTAGO Major Decreased metabolism of Nefazodone caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [43]
Aliskiren DM1BV7W Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [90]
Levamlodipine DM92S6N Moderate Decreased metabolism of Nefazodone caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Tolvaptan DMIWFRL Major Decreased metabolism of Nefazodone caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [43]
Retapamulin DM9JXB7 Minor Decreased metabolism of Nefazodone caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [91]
TP-434 DM5A31S Minor Decreased metabolism of Nefazodone caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [92]
Suvorexant DM0E6S3 Major Decreased metabolism of Nefazodone caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [43]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Nefazodone caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
ITI-007 DMUQ1DO Major Decreased metabolism of Nefazodone caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Quazepam DMY4D87 Moderate Decreased metabolism of Nefazodone caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [95]
Estazolam DMZGXUM Moderate Decreased metabolism of Nefazodone caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [95]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Nefazodone and Polyethylene glycol. Irritable bowel syndrome [DD91] [96]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Nefazodone caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [97]
Naloxegol DML0B41 Major Decreased metabolism of Nefazodone caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [43]
Pemigatinib DM819JF Major Decreased metabolism of Nefazodone caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [53]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Nefazodone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [53]
Crizotinib DM4F29C Major Decreased metabolism of Nefazodone caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [43]
Brigatinib DM7W94S Major Decreased metabolism of Nefazodone caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
Ceritinib DMB920Z Major Decreased metabolism of Nefazodone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [43]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Nefazodone caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [99]
PF-06463922 DMKM7EW Major Decreased metabolism of Nefazodone caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [100]
Osimertinib DMRJLAT Major Decreased metabolism of Nefazodone caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [101]
Capmatinib DMYCXKL Major Decreased metabolism of Nefazodone caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Selpercatinib DMZR15V Major Decreased metabolism of Nefazodone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [53]
Artemether DM48QOT Major Decreased metabolism of Nefazodone caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [43]
Halofantrine DMOMK1V Major Decreased metabolism of Nefazodone caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [103]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Nefazodone caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [43]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Nefazodone and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [104]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Nefazodone and Idelalisib. Mature B-cell leukaemia [2A82] [105]
IPI-145 DMWA24P Major Decreased metabolism of Nefazodone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [106]
Acalabrutinib DM7GCVW Major Decreased metabolism of Nefazodone caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [107]
Ibrutinib DMHZCPO Major Decreased metabolism of Nefazodone caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [43]
Ponatinib DMYGJQO Major Decreased metabolism of Nefazodone caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [43]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Nefazodone caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [108]
Selumetinib DMC7W6R Major Decreased metabolism of Nefazodone caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [109]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Nefazodone caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [43]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Nefazodone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [110]
Ubrogepant DM749I3 Major Decreased metabolism of Nefazodone caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [111]
Rimegepant DMHOAUG Moderate Decreased metabolism of Nefazodone caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [112]
Exjade DMHPRWG Moderate Decreased metabolism of Nefazodone caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [113]
Flibanserin DM70DTN Major Decreased metabolism of Nefazodone caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [114]
Panobinostat DM58WKG Major Decreased metabolism of Nefazodone caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [115]
Siponimod DM2R86O Major Decreased metabolism of Nefazodone caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [43]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Nefazodone and Ozanimod. Multiple sclerosis [8A40] [41]
Deflazacort DMV0RNS Major Decreased metabolism of Nefazodone caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [53]
Romidepsin DMT5GNL Moderate Decreased metabolism of Nefazodone caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [116]
Fedratinib DM4ZBK6 Major Decreased metabolism of Nefazodone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [53]
Nilotinib DM7HXWT Major Decreased metabolism of Nefazodone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
Ruxolitinib DM7Q98D Major Decreased metabolism of Nefazodone caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [117]
Dasatinib DMJV2EK Major Decreased metabolism of Nefazodone caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
E-2007 DMJDYNQ Minor Decreased metabolism of Nefazodone caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [53]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Nefazodone and Bupropion. Nicotine use disorder [6C4A] [118]
Entrectinib DMMPTLH Major Decreased metabolism of Nefazodone caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [43]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Nefazodone and Lorcaserin. Obesity [5B80-5B81] [119]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Nefazodone and Dexfenfluramine. Obesity [5B80-5B81] [40]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Nefazodone caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [120]
S-297995 DM26IH8 Moderate Decreased metabolism of Nefazodone caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [53]
Olaparib DM8QB1D Major Decreased metabolism of Nefazodone caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [43]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nefazodone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [121]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Nefazodone and Oxymorphone. Pain [MG30-MG3Z] [70]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Nefazodone and Dezocine. Pain [MG30-MG3Z] [70]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Nefazodone and Safinamide. Parkinsonism [8A00] [41]
Istradefylline DM20VSK Major Decreased metabolism of Nefazodone caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [122]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Nefazodone and Rasagiline. Parkinsonism [8A00] [41]
Pimavanserin DMR7IVC Major Decreased metabolism of Nefazodone caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [123]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Nefazodone caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [51]
Abametapir DM2RX0I Moderate Decreased metabolism of Nefazodone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [124]
Lefamulin DME6G97 Major Decreased clearance of Nefazodone due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [125]
Ergonovine DM0VEC1 Major Decreased metabolism of Nefazodone caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [126]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nefazodone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [127]
ABIRATERONE DM8V75C Minor Decreased metabolism of Nefazodone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [128]
Enzalutamide DMGL19D Moderate Decreased metabolism of Nefazodone caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [129]
Darolutamide DMV7YFT Minor Decreased metabolism of Nefazodone caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [130]
Silodosin DMJSBT6 Major Decreased metabolism of Nefazodone caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [43]
Finasteride DMWV3TZ Moderate Decreased metabolism of Nefazodone caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [51]
Ambrisentan DMD1QXW Minor Decreased metabolism of Nefazodone caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [131]
Riociguat DMXBLMP Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [43]
Everolimus DM8X2EH Major Decreased metabolism of Nefazodone caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [43]
Axitinib DMGVH6N Major Decreased metabolism of Nefazodone caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [43]
Temsirolimus DMS104F Major Increased metabolism of Nefazodone caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [43]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Nefazodone caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [132]
Upadacitinib DM32B5U Major Decreased metabolism of Nefazodone caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [133]
Tofacitinib DMBS370 Major Decreased metabolism of Nefazodone caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [43]
Dexamethasone DMMWZET Moderate Decreased metabolism of Nefazodone caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [132]
Quetiapine DM1N62C Major Decreased metabolism of Nefazodone caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [134]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Nefazodone caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [135]
Iloperidone DM6AUFY Major Decreased metabolism of Nefazodone caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [136]
Avanafil DM75CXN Major Decreased metabolism of Nefazodone caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [43]
Voxelotor DMCS6M5 Major Decreased metabolism of Nefazodone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [137]
LDE225 DMM9F25 Major Decreased metabolism of Nefazodone caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [138]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nefazodone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [53]
Larotrectinib DM26CQR Major Decreased metabolism of Nefazodone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Nefazodone caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [51]
Docetaxel DMDI269 Major Decreased metabolism of Nefazodone caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [139]
Trabectedin DMG3Y89 Major Decreased metabolism of Nefazodone caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Armodafinil DMGB035 Minor Decreased metabolism of Nefazodone caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Taxol DMUOT9V Moderate Decreased metabolism of Nefazodone caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [140]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nefazodone caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [53]
Fostamatinib DM6AUHV Major Decreased metabolism of Nefazodone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [141]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nefazodone due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [121]
As-1670542 DMV05SW Moderate Decreased metabolism of Nefazodone caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [53]
Apixaban DM89JLN Moderate Decreased metabolism of Nefazodone caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [53]
Brilinta DMBR01X Major Decreased metabolism of Nefazodone caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [43]
Cabozantinib DMIYDT4 Major Decreased metabolism of Nefazodone caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [43]
Saxagliptin DMGXENV Moderate Decreased metabolism of Nefazodone caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [53]
Elagolix DMB2C0E Major Decreased metabolism of Nefazodone caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [142]
Fluticasone DMGCSVF Major Decreased metabolism of Nefazodone caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [143]
Propafenone DMPIBJK Moderate Decreased metabolism of Nefazodone caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [144]
⏷ Show the Full List of 186 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nefazodone 50 mg tablet 50 mg Oral Tablet Oral
Nefazodone 100 mg tablet 100 mg Oral Tablet Oral
Nefazodone 250 mg tablet 250 mg Oral Tablet Oral
Nefazodone 150 mg tablet 150 mg Oral Tablet Oral
Nefazodone 200 mg tablet 200 mg Oral Tablet Oral
Nefazodone Hydrochloride 150mg tablet 150mg Tablet Oral
Nefazodone Hydrochloride 50mg tablet 50mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7247).
3 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
4 BDDCS applied to over 900 drugs
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
10 Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
11 Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
30 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
31 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
32 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
33 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
34 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
35 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
36 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
37 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
38 The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
39 Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2. [PMID: 7476638]
40 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
41 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
42 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
43 Cerner Multum, Inc. "Australian Product Information.".
44 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
45 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
46 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
47 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
48 Multum Information Services, Inc. Expert Review Panel.
49 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
50 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
51 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
52 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
53 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
54 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
55 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
56 Lee DO, Lee CD "Serotonin syndrome in a child associated with erythromycin and sertraline." Pharmacotherapy 19 (1999): 894-6. [PMID: 10417041]
57 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
58 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
59 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
60 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
61 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
62 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
63 Adson DE, Kotlyar M "A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report." J Clin Psychopharmacol 21 (2001): 618-9. [PMID: 11763013]
64 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
65 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
66 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
67 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
68 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
69 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
70 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
71 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
72 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
73 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
74 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
75 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
76 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
77 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
78 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
79 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
80 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
81 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
82 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
83 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
84 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
85 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
86 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
87 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
88 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
89 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
90 Canadian Pharmacists Association.
91 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
92 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
93 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
94 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
95 Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
96 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
97 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
98 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
99 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
100 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
101 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
102 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
103 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
104 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
105 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
106 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
107 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
108 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
109 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
110 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
111 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
112 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
113 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
115 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
116 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
117 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
118 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
119 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
120 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
121 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
122 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
123 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
124 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
125 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
126 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
127 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
128 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
129 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
130 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
131 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
132 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
133 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
134 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
135 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
136 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
137 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
138 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
139 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
140 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
141 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
142 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
143 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
144 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.